Skip to main content
. Author manuscript; available in PMC: 2009 Jun 20.
Published in final edited form as: Virology. 2008 Apr 28;376(1):112–123. doi: 10.1016/j.virol.2008.03.022

Fig. 1.

Fig. 1

Role of complement in the in vitro neutralization of SV5, MuV and HPIV2 by human serum. One hundred PFU of SV5 (panel A), MuV (panel B) or HPIV2 (panel C) were incubated for 1 h at 37 °C with PBS (left hatched bars) or with either normal human serum (NHS, grey bars) or heat-inactivated serum (HI, black bars). Remaining infectious titers were determined by plaque assays. Results represent the average of six experiments, with error bars representing standard deviations. Numbers denote donor number. (*) indicates that no plaques were detected in these samples. For panels A and B, differences between NHS- and HI-treated samples were statistically significant, p < 0.001.